FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Anowing Address of Reporting Forder Statement (Month/Day/Year) Anowing Anna 06/09/2021 ast) (First) (Middle) 06/09/2021 VO NAUTILUS BIOTECHNOLOGY, INC. 06/09/2021 25 PONTIUS AVE N, STE 202 1 treet) 1 EATTLE WA 98109 2 City) (State) City) (State) Table I - Non-Derivation		er 10% Owner Other (specify ed	below) 6. In	dividual or Joint/Gro X Form filed by C	f Original Filed (Month/Day/Year) up Filing (Check Applicable Line) One Reporting Person More than One Reporting Person
ZO NAUTILUS BIOTECHNOLOGY, INC. 25 PONTIUS AVE N, STE 202 treet) EATTLE WA 98109 City) (State) (Zip) Table I - Non-Deriva Title of Security (Instr. 4) 2.	(Check all applicable) Director X Officer (give title below) CFO and Treasure ative Securities Beneficially Own	10% Owner Other (specify Pr ed	below) 6. In	dividual or Joint/Gro X Form filed by C	up Filing (Check Applicable Line) One Reporting Person
Title of Security (Instr. 4)	Amount of Securities Beneficially 3				
		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)	
	ive Securities Beneficially Owned rants, options, convertible securi				
	3. Title and Amount of Securities Underlying Deriva Security (Instr. 4)		4. Conversion or Exercise Price of	e or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date	Title	Amount or Number of Shares	Derivative Security	(Instr. 5)	
tock Option (Right to Buy) (1) 12/03/2030	Common Stock	435,368	1.14	D	

Explanation of Responses:

1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan) through each vesting date, 13/49ths of the shares subject to the Option shall vest on the thirteen (13) month anniversary of the Vesting Commencement Date (as defined below), and one forty-ninth (1/49th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is December 3, 2020.

Remarks:

Exhibit 24: Power of Attorney

/s/ Anna Mowry ** Signature of Reporting Person 06/09/2021 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Nautilus Biotechnology, Inc. (the "Company"), hereby constitutes and appoints Sujal Patel 1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion det 2. do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national assoc: The undersigned hereby ratifies and confirms all that said attorneys in-fact and agent shall do or cause to be done by virtue hereof. The under This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 9th day of June, 2021.

Signature: /s/ Anna Mowry

Print Name: Anna Mowry